Our robust clinical pipeline includes small molecule, biologic and cellular therapies for the treatment of cancer. The Athenex team continues to fuel the rapid expansion of this clinical pipeline now comprised of nine total IND’s.

Taken together, our clinical pipeline balances a range of therapeutic approaches for the treatment of cancer to enable us to improve the lives of cancer patients.

ProgramDrug CandidateIndicationPre-ClinicalPhase 1Phase 2Phase 3Stage
OrascoveryOral paclitaxel + encequidarMetastatic breast cancer
RECEIVED CRL FROM FDA
Phase 3 — RECEIVED CRL FROM FDA
OrascoveryOral paclitaxel + encequidarAngiosarcoma
Phase 2
OrascoveryOral paclitaxel + encequidar w/ dostarlimab*Neoadjuvant breast cancer
(I-SPY 2)
Phase 2
OrascoveryOral paclitaxel + encequidar w/ ramucirumab**Gastric cancer
Phase 1
OrascoveryOral paclitaxel + encequidar w/ pembrolizumabSolid tumors
Phase 1
OrascoveryOral irinotecan + encequidarSolid tumors
Phase 1
OrascoveryOral docetaxel + encequidarSolid tumors
Phase 1
OrascoveryOral topotecan + encequidarSolid tumors
Phase 1
OrascoveryOral eribulin + encequidarSolid tumors
Phase 1
Src Kinase InhibitionTirbanibulin ointmentActinic keratosis
FDA Approved
Phase 3 — FDA Approved
TCR-T ImmunotherapyTCRT-ESO-A2Multiple tumors
Phase 1
Arginase Deprivation TherapyPT01Multiple tumors
Pre-clinical
* Collaboration with Quantum Leap Healthcare Collaborative and GlaxoSmithKline
** Collaboration with Eli Lilly and Company, makers of ramucirumab

Technology Platforms